Trial Profile
A Phase 1/2, Multi-Center, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jan 2018
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Elotuzumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 15 Jan 2018 Results of pooled data from five trials assessing role of elotuzumab in the treatment of relapsed or refractory multiple myeloma, were published in the American Journal of Health-System Pharmacy.
- 27 Feb 2012 Planned number of patients changed from 49 to 60 as reported by ClinicalTrials.gov.
- 27 Feb 2012 Planned End Date changed from 1 Sep 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.